stoxline Quote Chart Rank Option Currency Glossary
  
Aethlon Medical, Inc. (AEMD)
1.7  0.01 (0.59%)    02-23 14:33
Open: 1.63
High: 1.74
Volume: 3,334
  
Pre. Close: 1.69
Low: 1.63
Market Cap: 4(M)
Technical analysis
2024-02-23 4:34:48 PM
Short term     
Mid term     
Targets 6-month :  2.22 1-year :  2.45
Resists First :  1.9 Second :  2.09
Pivot price 1.72
Supports First :  1.6 Second :  1.33
MAs MA(5) :  1.68 MA(20) :  1.74
MA(100) :  1.8 MA(250) :  2.86
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  37.9 D(3) :  31.5
RSI RSI(14): 39.7
52-week High :  7.19 Low :  1.39
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ AEMD ] has closed above bottom band by 36.0%. Bollinger Bands are 65.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.74 - 1.75 1.75 - 1.76
Low: 1.61 - 1.62 1.62 - 1.63
Close: 1.68 - 1.7 1.7 - 1.72
Company Description

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.

Headline News

Wed, 21 Feb 2024
Aethlon Medical explores synergies with Santersus devices By Investing.com - Investing.com

Thu, 15 Feb 2024
Earnings call: Aethlon Medical Q3 FY2024 results and trials update By Investing.com - Investing.com

Thu, 15 Feb 2024
Aethlon Medical, Inc. (NASDAQ:AEMD) Q3 2024 Earnings Call Transcript - Yahoo Finance

Mon, 12 Feb 2024
Aethlon Medical Inc expected to post a loss of $1.23 a share - Earnings Preview - XM

Fri, 24 Nov 2023
Why Faraday Future Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Aethlon - Benzinga

Thu, 16 Nov 2023
Aethlon Medical, Inc. (NASDAQ:AEMD) Q2 2024 Earnings Call Transcript - Insider Monkey

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical Devices
Shares Out 0 (M)
Shares Float 3 (M)
Held by Insiders 2.45e+006 (%)
Held by Institutions 1.8 (%)
Shares Short 53 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.157e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -2 %
Return on Assets (ttm) 73.8 %
Return on Equity (ttm) -41.5 %
Qtrly Rev. Growth 574250 %
Gross Profit (p.s.) 0
Sales Per Share -40.56
EBITDA (p.s.) 0
Qtrly Earnings Growth -4.8 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -10 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.05
Price to Cash Flow 0.78
Stock Dividends
Dividend 0
Forward Dividend 7550
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android